Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016;354:618–622.
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53.
   PubMed Web of Science ®Google Scholar
• Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664–672.
   PubMed Web of Science ®Google Scholar
• Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer–what limits limited disease? Lung Cancer Amst Neth. 2002;37:271–276.
   PubMed Web of Science ®Google Scholar
• Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1985;3:1471–1477.
   PubMed Web of Science ®Google Scholar
• Kalemkerian GP, Akerley W, Bogner P, et al. Small cell lung cancer. J Natl Compr Cancer Netw JNCCN. 2013;11:78–98.
   PubMed Web of Science ®Google Scholar
• NCCN.org. NCCN clinical practice guidelines in oncology (NCCN guidelines®) for small cell lung cancer. Version 1.2019 [Internet]. [cited 2019 May 15]. Available from: https://www.nccn.org
   Google Scholar
• Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:2038–2043.
   PubMed Web of Science ®Google Scholar
• Lara PN, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol. 2009;27:2530–2535.
   PubMed Web of Science ®Google Scholar
• Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16–23.
   PubMed Web of Science ®Google Scholar
• Ardizzoni A, Tiseo M, Boni L. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. Eur J Cancer Oxf Engl 1990. 2014;50:2211–2218.
   PubMed Web of Science ®Google Scholar
• Lo Russo G, Macerelli M, Platania M, et al. Small-cell lung cancer: clinical management and unmet needs new perspectives for an old problem. Curr Drug Targets. 2017;18:341–362.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Agelidou A, Agelaki S, et al. A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Lung Cancer (Amst Neth). 2009;65:187–191.
   PubMed Web of Science ®Google Scholar
• Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1992;10:1225–1229.
   PubMed Web of Science ®Google Scholar
• Kondo R, Watanabe S, Shoji S, et al. A phase II study of irinotecan for patients with previously treated small-cell lung cancer. Oncology. 2018;94:223–232.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–2229.
   PubMed Web of Science ®Google Scholar
• Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): first report of a randomized expansion cohort from CheckMate 032. J Clin Oncol. 35(15_suppl) [Internet]. [cited 2019 Feb 25]. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.35.15_suppl.8503
   Google Scholar
• Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 Study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:3823–3829.
   PubMed Web of Science ®Google Scholar
• Gelsomino F, Leonetti A, Rihawi K, et al. Immune checkpoint inhibition in small cell lung cancer: a key to reach an unmet need? Transl Cancer Res. 2017;6:S1484–S1488.
   Web of Science ®Google Scholar
• Leonetti A, Facchinetti F, Minari R, et al. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges. Cell Oncol Dordr. 2019.
   PubMed Web of Science ®Google Scholar
• Kelland LR. Preclinical perspectives on platinum resistance. Drugs. 2000;59(Suppl 4):1–8. discussion 37-38.
   PubMed Web of Science ®Google Scholar
• Perego P, Robert J. Oxaliplatin in the era of personalized medicine: from mechanistic studies to clinical efficacy. Cancer Chemother Pharmacol. 2016;77:5–18.
   PubMed Web of Science ®Google Scholar
• Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther. 1987;34:155–166.
   PubMed Web of Science ®Google Scholar
• Pinto AL, Lippard SJ. Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta. 1985;780:167–180.
   PubMed Web of Science ®Google Scholar
• Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol. 1993;15:191–219.
   PubMed Web of Science ®Google Scholar
• Shapiro GI, Harper JW. Anticancer drug targets: cell cycle and checkpoint control. J Clin Invest. 1999;104:1645–1653.
   PubMed Web of Science ®Google Scholar
• Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279.
   PubMed Web of Science ®Google Scholar
• Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275:39435–39443.
   PubMed Web of Science ®Google Scholar
• Losa JH, Cobo CP, Viniegra JG, et al. Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene. 2003;22:3998–4006.
   PubMed Web of Science ®Google Scholar
• Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7:775–783.
   PubMed Web of Science ®Google Scholar
• Avan A, Narayan R, Giovannetti E, et al. Role of Akt signaling in resistance to DNA-targeted therapy. World J Clin Oncol. 2016;7:352–369.
   PubMed Web of Science ®Google Scholar
• Appella E, Anderson CW. Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem. 2001;268:2764–2772.
   PubMedGoogle Scholar
• Hershberger PA, McGuire TF, Yu W-D, et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther. 2002;1:821–829.
   PubMed Web of Science ®Google Scholar
• Smith ML, Kontny HU, Bortnick R, et al. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res. 1997;230:61–68.
   PubMed Web of Science ®Google Scholar
• Makin GW, Corfe BM, Griffiths GJ, et al. Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate. Embo J. 2001;20:6306–6315.
   PubMed Web of Science ®Google Scholar
• Ferreira CG, Epping M, Kruyt FAE, et al. Apoptosis: target of cancer therapy. Clin Cancer Res. 2002;8:2024–2034.
   PubMed Web of Science ®Google Scholar
• Del Bello B, Valentini MA, Zunino F, et al. Cleavage of Bcl-2 in oxidant- and cisplatin-induced apoptosis of human melanoma cells. Oncogene. 2001;20:4591–4595.
   PubMed Web of Science ®Google Scholar
• Müller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188:2033–2045.
   PubMed Web of Science ®Google Scholar
• Catani MV, Costanzo A, Savini I, et al. Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage. Biochem J. 2002;364:441–447.
   PubMed Web of Science ®Google Scholar
• Kharbanda S, Pandey P, Yamauchi T, et al. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol. 2000;20:4979–4989.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Holden SA, Kelley MJ, et al. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res. 1987;47:388–393.
   PubMed Web of Science ®Google Scholar
• Kool M, de Haas M, Scheffer GL, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997;57:3537–3547.
   PubMed Web of Science ®Google Scholar
• Samimi G, Safaei R, Katano K, et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10:4661–4669.
   PubMed Web of Science ®Google Scholar
• Kim ES. Chemotherapy resistance in lung cancer. Adv Exp Med Biol. 2016;893:189–209.
   PubMed Web of Science ®Google Scholar
• Howell SB, Safaei R, Larson CA, et al. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010;77:887–894.
   PubMed Web of Science ®Google Scholar
• Hamaguchi K, Godwin AK, Yakushiji M, et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res. 1993;53:5225–5232.
   PubMed Web of Science ®Google Scholar
• Goto S, Iida T, Cho S, et al. Overexpression of glutathione S-transferase π enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res. 1999;31:549–558.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Kondo A, Kawasaki K, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell. 2001;14:305–315.
   PubMedGoogle Scholar
• Kurokawa H, Ishida T, Nishio K, et al. γ-Glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun. 1995;216:258–264.
   PubMed Web of Science ®Google Scholar
• Meijer C, Mulder NH, Hospers GA, et al. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Br J Cancer. 1990;62:72–77.
   PubMed Web of Science ®Google Scholar
• Caffrey PB, Frenkel GD, McAndrew KL, et al. A model of the development of cisplatin resistance in human small cell lung cancer xenografts. Vivo Athens Greece. 2016;30:745–749.
   PubMed Web of Science ®Google Scholar
• Campling BG, Baer K, Baker HM, et al. Do glutathione and related enzymes play a role in drug resistance in small cell lung cancer cell lines? Br J Cancer. 1993;68:327–335.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Avan A, Ruiz MG, et al. Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer. Anticancer Res. 2014;34:435–442.
   PubMed Web of Science ®Google Scholar
• Heyza JR, Lei W, Watza D, et al. Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:2523–2536.
   PubMed Web of Science ®Google Scholar
• Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res Off J Am Assoc Cancer Res. 1998;4:1–6.
   PubMed Web of Science ®Google Scholar
• He Q, Liang CH, Lippard SJ. Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. Proc Natl Acad Sci. 2000;97:5768–5772.
   PubMed Web of Science ®Google Scholar
• Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996;56:556–562.
   PubMed Web of Science ®Google Scholar
• Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7:2168–2181.
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Liu J, Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis Int J Program Cell Death. 2002;7:23–29.
   PubMed Web of Science ®Google Scholar
• Chiao C, Carothers AM, Grunberger D, et al. Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells. Cancer Res. 1995;55:3576–3583.
   PubMed Web of Science ®Google Scholar
• Stefanaki K, Rontogiannis D, Vamvouka C, et al. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res. 1998;18:1167–1173.
   PubMed Web of Science ®Google Scholar
• Shoemaker AR, Mitten MJ, Adickes J, et al. Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:3268–3277.
   PubMed Web of Science ®Google Scholar
• Hann CL, Daniel VC, Sugar EA, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68:2321–2328.
   PubMed Web of Science ®Google Scholar
• Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25:56–64.
   PubMed Web of Science ®Google Scholar
• Khan KH, Blanco-Codesido M, Molife LR. Cancer therapeutics: targeting the apoptotic pathway. Crit Rev Oncol Hematol. 2014;90:200–219.
   PubMed Web of Science ®Google Scholar
• Cuya SM, Bjornsti M-A, van Waardenburg RCAM. DNA topoisomerase-targeting chemotherapeutics: what’s new? Cancer Chemother Pharmacol. 2017;80:1–14.
   PubMed Web of Science ®Google Scholar
• Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5:1189–1196.
   PubMed Web of Science ®Google Scholar
• Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer. 2009;9:338–350.
   PubMed Web of Science ®Google Scholar
• Basili S, Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. Expert Opin Ther Pat. 2009;19:555–574.
   PubMed Web of Science ®Google Scholar
• Alpsoy A, Yasa S, Gündüz U. Etoposide resistance in MCF-7 breast cancer cell line is marked by multiple mechanisms. Biomed Pharmacother Biomed Pharmacother. 2014;68:351–355.
   PubMed Web of Science ®Google Scholar
• Wang Y-L, Yan Y-L, Zhou N-J, et al. Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP. Chin Med J. 2010;123:3299–3303.
   PubMed Web of Science ®Google Scholar
• Brock I, Hipfner DR, Nielsen BS, et al. Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res. 1995;55:459–462.
   PubMed Web of Science ®Google Scholar
• Minato K, Kanzawa F, Nishio K, et al. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol. 1990;26:313–317.
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD, Ordonez JV, et al. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br J Cancer. 1995;72:535–542.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Gündüz U. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance. Biomed Pharmacother. 2012;66:29–35.
   PubMed Web of Science ®Google Scholar
• de Las Alas MM, Aebi S, Fink D, et al. Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. JNCI J Natl Cancer Inst. 1997;89:1537–1541.
   Web of Science ®Google Scholar
• Beretta GL, Gatti L, Perego P, et al. Camptothecin resistance in cancer: insights into the molecular mechanisms of a DNA-damaging drug. Curr Med Chem. 2013;20:1541–1565.
   PubMed Web of Science ®Google Scholar
• Takano M, Sugiyama T. UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. Pharmacogenomics Pers Med. 2017;10:61–68.
   PubMed Web of Science ®Google Scholar
• Etienne-Grimaldi M-C, Boyer J-C, Thomas F, et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol. 2015;29:219–237.
   PubMed Web of Science ®Google Scholar
• Takano M, Kato M, Yoshikawa T, et al. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study. Oncology. 2009;76:315–321.
   PubMed Web of Science ®Google Scholar
• Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:3061–3068.
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38. J Clin Pharmacol. 2004;44:854–860.
   PubMed Web of Science ®Google Scholar
• Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature. 1992;356:356–358.
   PubMed Web of Science ®Google Scholar
• Byers LA, Wang J, Nilsson MB, et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012;2:798–811.
   PubMed Web of Science ®Google Scholar
• Teicher BA, Silvers T, Selby M, et al. Small cell lung carcinoma cell line screen of etoposide/carboplatin plus a third agent. Cancer Med. 2017;6:1952–1964.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Zhang G, Deng X, et al. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. Cancer Med. 2014;3:1579–1594.
   PubMed Web of Science ®Google Scholar
• Lallo A, Frese KK, Morrow CJ, et al. The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:5153–5164.
   PubMed Web of Science ®Google Scholar
• Atrafi F, Groen HJM, Byers LA, et al. A phase I dose-escalation study of veliparib combined with carboplatin and etoposide in patients with extensive-stage small cell lung cancer and other solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25:496–505.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Dahlberg SE, Khan SA, et al. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN cancer research group (E2511). Lung Cancer (Amst Neth). 2015;89:66–70.
   PubMed Web of Science ®Google Scholar
• de Bono J, Ramanathan RK, Mina L, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 2017;7:620–629.
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Dahlberg SE, Sica GL, et al. Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study. J Clin Oncol 2017; 35 (suppl, abstract 8505).
   Google Scholar
• Pietanza MC, Waqar SN, Krug LM, et al. Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:2386–2394.
   PubMed Web of Science ®Google Scholar
• Murai J, Tang S-W, Leo E, et al. SLFN11 blocks stressed replication forks independently of ATR. Mol Cell. 2018;69:371–384.e6.
   PubMed Web of Science ®Google Scholar
• Lok BH, Gardner EE, Schneeberger VE, et al. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:523–535.
   PubMed Web of Science ®Google Scholar
• Allison Stewart C, Tong P, Cardnell RJ, et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. 2017;8:28575–28587.
   PubMedGoogle Scholar
• Saito M, Saito K, Shiraishi K, et al. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol. 2018;8:310–314.
   PubMed Web of Science ®Google Scholar
• Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. 2015;7:302ra136.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Isse K, Fujihira T, et al. Prevalence of delta-like protein 3 expression in patients with small cell lung cancer. Lung Cancer (Amst Neth). 2018;115:116–120.
   PubMed Web of Science ®Google Scholar
• Ladi E, Nichols JT, Ge W, et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 2005;170:983–992.
   PubMed Web of Science ®Google Scholar
• Chapman G, Sparrow DB, Kremmer E, et al. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum Mol Genet. 2011;20:905–916.
   PubMed Web of Science ®Google Scholar
• Hassan WA, Yoshida R, Kudoh S, et al. Evaluation of role of Notch3 signaling pathway in human lung cancer cells. J Cancer Res Clin Oncol. 2016;142:981–993.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Pietanza MC, Bauer TM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Morgensztern D, Le Moulec S, et al. Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: results from the phase 2 TRINITY study. J Clin Oncol. 2018;36:8507.
   Web of Science ®Google Scholar
• AbbVie announces results from phase 2 study evaluating rovalpituzumab tesirine (Rova-T) for third-line treatment of patients with DLL3-expressing relapsed/refractory small cell lung cancer | AbbVie News Center [Internet]. [cited 2019 May 15]. Available from: https://news.abbvie.com/news/abbvie-announces-results-from-phase-2-study-evaluating-rovalpituzumab-tesirine-rova-t-for-third-line-treatment-patients-with-dll3-expressing-relapsedrefractory-small-cell-lung-cancer.htm
   Google Scholar